Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2008-09-10
2011-12-13
Russel, Jeffrey E (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S004800, C514S005300, C514S008600, C514S016700, C514S021300
Reexamination Certificate
active
08076281
ABSTRACT:
A method and pharmaceutical composition for inhibiting the effect of glucocorticoids, particularly dexamethasone, which suppress growth hormone secretion, by administering ghrelin or a ghrelin analogue, for example, [Aib2, Glu3(NH-hexyl)]hGhrelin(1-28)-NH2(SEQ ID NO:2) or other suitable ghrelin agonist, to counteract the catabolic effects of said dexamethasone and other natural glucocorticoids.
REFERENCES:
patent: 7385026 (2008-06-01), Kangawa et al.
patent: 7666833 (2010-02-01), Ghigo et al.
patent: 2004/0092733 (2004-05-01), Burton et al.
patent: 2005/0143448 (2005-06-01), Grenard et al.
patent: 2005/0158325 (2005-07-01), Hammerbeck et al.
patent: 2005/0272648 (2005-12-01), Dong et al.
patent: 2006/0025566 (2006-02-01), Hoveyda et al.
patent: 1506786 (2005-02-01), None
patent: 97/24369 (1997-07-01), None
patent: 2004/009616 (2004-01-01), None
Huysman et al. A Randomized, Placebo-Controlled GH Trial in Very Preterm Infants . . . Pediatric Research. 2005, vol. 58, No. 4, pp. 705-712.
Leal-Cerro et al. Ghrelin is No Longer Able to Stimulate Growth Hormone Secretion . . . Clinical Neuroendocrinology. 2002, vol. 76, pp. 390-396.
Barnes, P. J., “Inhaled Glucocorticoids for Asthma,” NEJM, 1995, 332:868-875.
Laron, Z. et al., “Intranasal administration of the GHRP hexarelin accelerates growth in short children,” Clinical Endo., 1995, 43:631-635.
Reid, I. R., “Glucocorticoid osteoporosis—mechanisms and management,” European J. Endo., 1997, 137:209-217.
Weiler, H. A. et al., “Longitudinal assessment of growth and bone mineral accretion in prematurely born infants treated for chronic lung disease with dexamethasone,” Early Human Dev., 1997, 47:271-286.
Culler Michael DeWitt
Dong Zheng Xin
Giustina Andrea
Tulipano Giovanni
Ball Pamela C.
Feeney Alan F.
IPSEN Pharma S.A.S.
Russel Jeffrey E
Yankwich & Associates
LandOfFree
Use of a ghrelin agonist to improve the catabolic effects of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of a ghrelin agonist to improve the catabolic effects of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of a ghrelin agonist to improve the catabolic effects of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4312864